Lilly’s Kisunla Postmarketing Studies Include Maintenance Dosing, But No Safety Trial

 
• By Sue Sutter
  
Alzheimer's patient
Lilly will assess maintenance dosing with Kisunla. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from Product Reviews